JPMorgan analyst Anne Samuel raised the firm’s price target on Iqvia to $263 from $257 and keeps an Overweight rating on the shares post the Q4 results. The firm sees a "consistent level of underlying growth" throughout 2023 with COVID roll-offs and currency pressure driving the second half of the year weighting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IQV:
- Iqvia sees FY23 adjusted EPS $10.26-$10.56, consensus $10.71
- Iqvia reports Q4 adjusted EPS $2.78, consensus $2.76
- Iqvia teams with Alibaba for cloud commercial & clinical solutions in China
- Pharma Industry Could Benefit from Rise in Medicine Spending
- Iqvia price target lowered to $260 from $266 at Baird